Home Reagents Clinical Chemistry Reagents Apolipoprotein A-II (Apo A-II)
Quality Guranteed Fast Delivery ad for support

Apolipoprotein A-II (Apo A-II)

Product Method Size Catalog Price Quantity
Apolipoprotein A-II (Apo A-II) Immunoturbidimetric R1 2x11, R2 2x5ml LP3867 $946.23
Shipping costs will be added at the checkout stage, click here for charges.
  • Format
    Liquid ready to use
  • Assay Range
    6.75 - 61.1mg/dl
Request Kit Insert

Intended Use

For the quantitative in vitro determination of Apolipoprotein A-II (Apo A-II) in serum and plasma. For use as an aid in assessing the risk of cardiovascular disease. This product is suitable for use on the RX Series instruments which includes the Rx Daytona and Rx Imola.

Clinical Significance

Lipoproteins are large complexes of molecules that transport lipids (primarily triglycerides and cholesterols) through the blood. Apolipoproteins are proteins on the surface of the lipoprotein complex that bind to specific enzymes or transport proteins on the cell membranes. This directs the lipoprotein to the proper site of metabolism.

Just as HDL and LDL are referred to as “good” and “bad” cholesterol, elevated levels of some apolipoproteins confer an increased cardiovascular risk while others have a protective effect. Apolipoproteins are a valuable addition to the lipid profile, supplying further information to researchers and clinicians. The genetic variants of the apolipoproteins can have a marked effect on cardiovascular risk and are linked with familial lipoprotein disorders such as hypertriglyceridemia.

Apolipoproteins and the ratios between them are useful in the assessment of cardiovascular risk in individuals with normal lipoprotein levels. They are also valuable in specific patient populations, for example identifying patients that would benefit from more rigorous treatment in secondary prevention.

Apolipoprotein A-II is a major constituent of High Density Lipoprotein (HDL) particles and plays an important role in the reverse cholesterol transport and lipid metabolism. The distribution of Apo A-I- in the HDL is primarily determined by the production rate of Apo A-II. Increased production of Apo A-II promotes atherosclerosis by decreasing the proportion of anti-atherogenic HDL containing Apo A-I.

Apo A-II is synthesized mainly in the liver and modulates lipoprotein lipase and hepatic triglyceride lipase. It also acts as a co-factor for Lecithin cholesterol acyltransferase which is involved in lipoprotein processing.


This method is based on the reaction of a sample containing human Apo A-II and specific antiserum to form an insoluble complex which can be measured turbidimetrically at 600 nm.